LH | Jotup

GL’s Multi-Protocol Emulation Test Suite for IP Networks

Retrieved on:

화요일, 2월 21, 2023

HTTP, CAP, GTP, S11, GGSN, LTE, CMOS, Generalized Multi-Protocol Label Switching, Wireless network, UES, Voice over LTE, GMLC, RTP, Air traffic control, Internet, GSM, MAPS, INAP, RNC, TDM, N10, SIGTRAN, UMTS, LCS, MAP, LMOS, Gateway, HLR, N12, Voice over NR, SLS, IMS, Emulation, FTP, IP, SGSN, GPRS, S13, SIP, SAS, N29, N51, Mobile phone, Video game, Printed circuit board, IUP (software), LG Corporation, S4, Voice over IP, LH, IUC, N4, Video, Analog

GL’s comprehensive Signaling and Traffic Emulation test equipment suite, commonly referred to as Message Automation and Protocol Simulation (MAPS™), provides a programmable, highly flexible, script based, multi-protocol, multi-interface emulation framework and makes it easy to perform cross-domain testing and transition tests to new technologies such as 5G.

Key Points:

GL’s comprehensive Signaling and Traffic Emulation test equipment suite, commonly referred to as Message Automation and Protocol Simulation (MAPS™), provides a programmable, highly flexible, script based, multi-protocol, multi-interface emulation framework and makes it easy to perform cross-domain testing and transition tests to new technologies such as 5G.
“GL’s MAPS™ test suite can emulate 5G, 4G, 3G, 2G and IMS networks.
The same versatile tool can also emulate VoIP (SIP), ED-137 (Air Traffic Control Protocols) and legacy networks such as SIGTRAN.
The test suite can work with GL’s High-Density Call Generator for IP & Wireless Networks , a specialized hardware platform for generating tens of thousands of simultaneous calls.

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

Retrieved on:

목요일, 2월 16, 2023

Revenue for the quarter was $3.67 billion, a decrease of (9.4%) from $4.06 billion in the fourth quarter of 2021.

Key Points:

Revenue for the quarter was $3.67 billion, a decrease of (9.4%) from $4.06 billion in the fourth quarter of 2021.
Operating income for the quarter was $90.7 million, or 2.5% of revenue, compared to $730.6 million, or 18.0%, in the fourth quarter of 2021.
Net earnings for the quarter were $76.1 million compared to $553.0 million in the fourth quarter of 2021.
Operating cash flow for the quarter was $653.6 million compared to $697.5 million in the fourth quarter of 2021.

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

Retrieved on:

목요일, 2월 9, 2023

Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea.

Key Points:

Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea.
Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services.
With over 19,000 people, Fortrea will provide Phase I through IV clinical trial management and commercialization solutions to pharmaceutical and biotechnology organizations around the world.
Until the spin-off is complete, the Clinical Development business and its products, services and offerings are still owned and operated by Labcorp.

Proov Announces Fourth Patent to Identify Fertile Window

Retrieved on:

월요일, 1월 30, 2023

Hormone, Luteinizing hormone, Ovulation, Health, Menstrual cycle, LH, Amazon, FSH, FDA, Progesterone, Patent, Urine, Fertility, Woman, Patient, Ovary, Birth control

BOULDER, Colo., Jan. 30, 2023 /PRNewswire/ -- Proov , a diagnostics company offering medical grade at-home tests and a support platform, is announcing today that it has received patent issue notification for its fourth utility patent.

Key Points:

BOULDER, Colo., Jan. 30, 2023 /PRNewswire/ -- Proov , a diagnostics company offering medical grade at-home tests and a support platform, is announcing today that it has received patent issue notification for its fourth utility patent.
Proov's fourth patent adds to Proov's industry-leading patent portfolio, related to the testing of PdG in urine in women.
The new patent encompasses a system that measures follicle-stimulating hormones (FSH), estrogen, LH, and progesterone markers in urine to pinpoint the fertile window in women.
Proov continues to lead the development of at-home hormone testing technologies to empower women, and has many additional related technologies covered by pending patent applications.

Wallbridge Mineral Resource Estimate Delivers Significant Increase in Grade at Detour-Fenelon Gold Trend Property

Retrieved on:

화요일, 1월 17, 2023

This translated into significant increases in gold grade at Fenelon, with an 85% increase in the grade of the Indicated resources and an 84% increase in the grade of Inferred resources, compared to the 2021 Fenelon maiden MRE.

Key Points:

This translated into significant increases in gold grade at Fenelon, with an 85% increase in the grade of the Indicated resources and an 84% increase in the grade of Inferred resources, compared to the 2021 Fenelon maiden MRE.
We look forward to carrying our positive exploration momentum into 2023.”
57% of the ounces of the Detour-Fenelon Gold Trend MRE are in the Indicated category.
Significant expansion potential exists at Fenelon and Martiniere as both gold deposits are open in multiple directions.
The mineral resources are categorized as Indicated and Inferred based on drill spacing, as well as geological and grade continuity.

Labcorp to Announce Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

Retrieved on:

수요일, 1월 18, 2023

Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, LH, Webcast, PIN, NYSE, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023.

Key Points:

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023.
The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website .
The call will be webcast live on the Labcorp Investor Relations website .
To access the webcast recording, visit the Labcorp Investor Relations website .

Labcorp Declares Quarterly Dividend

Retrieved on:

목요일, 1월 12, 2023

Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, LH, NYSE, Holding company, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

Key Points:

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

OB-GYN Mary Jane Minkin, M.D., Shares Considerations for Women’s Health Resolutions in 2023

Retrieved on:

목요일, 1월 5, 2023

Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.

Key Points:

Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.
"Making goals for the new year is a great way to re-evaluate one’s health routines," says Dr. Minkin.
“I encourage women to consider all the different changes – large or small – that they can make to improve their health and wellbeing from vaginal, sexual and reproductive health to mental health."
Dr. Minkin offers the following considerations for women’s health resolutions in the new year.

Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit

Retrieved on:

목요일, 1월 5, 2023

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.

Key Points:

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.
Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter.
At the time of the spin-off, Mr. Pike will serve as the chief executive officer and chairman of the Board of the independent, publicly listed company.
In the coming months, Labcorp will announce the Board of Directors of the new company, including its lead independent director.

Labcorp to Speak at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on:

화요일, 1월 3, 2023

Health, Hospitals, Clinical Trials, Research, Pharmaceutical, Science, Conference, NYSE, LH, Pharmaceutical industry, Broadcasting, Life insurance, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).

Key Points:

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).
A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.